• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

携带HIV-1 TatΔ51-59蛋白的重组流感病毒在小鼠体内诱导抗体和T细胞反应

Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.

作者信息

Garulli B, Di Mario G, Stillitano M G, Compagnoni D, Titti F, Cafaro A, Ensoli B, Kawaoka Y, Castrucci M R

机构信息

Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy ; Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, 00185 Rome, Italy.

Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

出版信息

Biomed Res Int. 2014;2014:904038. doi: 10.1155/2014/904038. Epub 2014 May 14.

DOI:10.1155/2014/904038
PMID:24949479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4053076/
Abstract

Recombinant influenza viruses hold promise as vectors for vaccines to prevent transmission of mucosal pathogens. In this study, we generated a recombinant WSN/TatΔ(51-59) virus in which Tat protein lacking residues 51 to 59 of the basic domain was inserted into the N-terminus of the hemagglutinin (HA) of A/WSN/33 virus. The TatΔ(51-59) insertion into the viral HA caused a 2-log reduction in viral titers in cell culture, compared with the parental A/WSN/33 virus, and severely affected virus replication in vivo. Nevertheless, Tat-specific antibodies and T cell responses were elicited upon a single intranasal immunization of BALB/c mice with WSN/TatΔ(51-59) virus. Moreover, Tat-specific immune responses were also detected following vaccine administration via the vaginal route. These data provide further evidence that moderately large HIV antigens can be delivered by chimeric HA constructs and elicit specific immune responses, thus increasing the options for the potential use of recombinant influenza viruses, and their derivatives, for prophylactic and therapeutic vaccines.

摘要

重组流感病毒有望作为预防黏膜病原体传播的疫苗载体。在本研究中,我们构建了一种重组WSN/TatΔ(51 - 59)病毒,其中缺失碱性结构域第51至59位残基的Tat蛋白被插入到A/WSN/33病毒血凝素(HA)的N端。与亲本A/WSN/33病毒相比,将TatΔ(51 - 59)插入病毒HA导致细胞培养中的病毒滴度降低了2个对数,并严重影响了病毒在体内的复制。然而,用WSN/TatΔ(51 - 59)病毒对BALB/c小鼠进行单次鼻内免疫后,可引发Tat特异性抗体和T细胞反应。此外,通过阴道途径接种疫苗后也检测到了Tat特异性免疫反应。这些数据进一步证明,中等大小的HIV抗原可通过嵌合HA构建体递送并引发特异性免疫反应,从而增加了重组流感病毒及其衍生物用于预防性和治疗性疫苗的潜在应用选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/749ce6344131/BMRI2014-904038.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/04fe61dfa106/BMRI2014-904038.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/cfb54c01d3d0/BMRI2014-904038.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/9899a07b3c07/BMRI2014-904038.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/bbd8f8c4d543/BMRI2014-904038.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/749ce6344131/BMRI2014-904038.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/04fe61dfa106/BMRI2014-904038.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/cfb54c01d3d0/BMRI2014-904038.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/9899a07b3c07/BMRI2014-904038.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/bbd8f8c4d543/BMRI2014-904038.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3d7/4053076/749ce6344131/BMRI2014-904038.005.jpg

相似文献

1
Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.携带HIV-1 TatΔ51-59蛋白的重组流感病毒在小鼠体内诱导抗体和T细胞反应
Biomed Res Int. 2014;2014:904038. doi: 10.1155/2014/904038. Epub 2014 May 14.
2
Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.用杆状病毒展示的H6血凝素疫苗免疫可保护小鼠免受致死性H6流感病毒攻击。
Antiviral Res. 2014 Sep;109:42-53. doi: 10.1016/j.antiviral.2014.06.002. Epub 2014 Jun 25.
3
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.用水泡性口炎病毒载体嵌合血凝素疫苗接种可保护小鼠免受不同流感病毒攻击毒株的侵害。
J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.
4
Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.新型改良安卡拉痘苗病毒(MVA)载体疫苗在小鼠体内对多种流感病毒亚型产生的交叉保护免疫。
Vaccine. 2013 Apr 3;31(14):1848-55. doi: 10.1016/j.vaccine.2013.01.038. Epub 2013 Feb 1.
5
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.用于诱导持久体液免疫介导的对小鼠流感广泛保护的鼻内腺病毒载体疫苗。
J Virol. 2014 Sep 1;88(17):9693-703. doi: 10.1128/JVI.00823-14. Epub 2014 Jun 11.
6
Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.携带嵌合血凝素缀合物的多聚体 M2 细胞外结构域的复制型重组流感病毒的免疫原性和功效。
Antiviral Res. 2017 Dec;148:43-52. doi: 10.1016/j.antiviral.2017.10.018. Epub 2017 Oct 26.
7
Exploring mucosal immunization with a recombinant influenza virus carrying an HIV-polyepitope in mice with pre-existing immunity to influenza.探讨携带 HIV 多表位的重组流感病毒在对流感存在预先免疫的小鼠中的黏膜免疫。
Vaccine. 2014 May 1;32(21):2501-6. doi: 10.1016/j.vaccine.2014.02.077. Epub 2014 Mar 21.
8
Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.蛋白转导结构域介导的流感 NP 亚单位疫苗在小鼠中产生强烈的免疫应答和抗流感病毒保护作用。
Emerg Microbes Infect. 2020 Dec;9(1):1933-1942. doi: 10.1080/22221751.2020.1812436.
9
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.神经氨酸酶抑制抗体滴度与对同一神经氨酸酶亚型的异源流感病毒株的保护作用相关。
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.01006-18. Print 2018 Sep 1.
10
Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.杆状病毒作为禽流感疫苗载体:不同载体形式引起的免疫应答差异。
Vaccine. 2010 Nov 10;28(48):7644-51. doi: 10.1016/j.vaccine.2010.09.048. Epub 2010 Sep 28.

引用本文的文献

1
IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice.IgGκ 信号肽增强流感载体疫苗对小鼠呼吸道合胞病毒感染的疗效。
Int J Mol Sci. 2023 Jul 14;24(14):11445. doi: 10.3390/ijms241411445.

本文引用的文献

1
Exploring mucosal immunization with a recombinant influenza virus carrying an HIV-polyepitope in mice with pre-existing immunity to influenza.探讨携带 HIV 多表位的重组流感病毒在对流感存在预先免疫的小鼠中的黏膜免疫。
Vaccine. 2014 May 1;32(21):2501-6. doi: 10.1016/j.vaccine.2014.02.077. Epub 2014 Mar 21.
2
Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.携带卵清蛋白CD4+和CD8+ T细胞表位的重组流感病毒的免疫原性
J Biomed Biotechnol. 2011;2011:497364. doi: 10.1155/2011/497364. Epub 2011 Oct 5.
3
The ins and outs of HIV-1 Tat.
HIV-1 Tat 的来龙去脉。
Traffic. 2012 Mar;13(3):355-63. doi: 10.1111/j.1600-0854.2011.01286.x. Epub 2011 Oct 11.
4
A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.一种基于 Tat 和 Env 蛋白的联合 HIV 疫苗在一项初步研究中具有免疫原性,并能保护猕猴免受粘膜 SHIV 挑战。
Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.
5
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.抗 HIV-1 Tat 治疗性免疫接种可降低接受高效抗逆转录病毒治疗(HAART)人群的免疫激活和调节性 T 细胞的丢失,并改善其免疫功能。
PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.
6
The preventive phase I trial with the HIV-1 Tat-based vaccine.HIV-1 基于 Tat 的疫苗的预防 I 期试验。
Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29.
7
Functions of Tat: the versatile protein of human immunodeficiency virus type 1.Tat 的功能:人类免疫缺陷病毒 1 型的多功能蛋白。
J Gen Virol. 2010 Jan;91(Pt 1):1-12. doi: 10.1099/vir.0.016303-0. Epub 2009 Oct 7.
8
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).用更高剂量的SHIV89.6P(cy243)再次攻击后,tat疫苗接种猴体内感染的控制情况
Viral Immunol. 2009 Apr;22(2):117-24. doi: 10.1089/vim.2008.0082.
9
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.HIV-1反式激活因子蛋白的I期治疗试验及长期随访
Vaccine. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7.
10
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control.精英控制者对HIV-1的黏膜免疫反应:免疫控制的一个潜在相关因素。
Blood. 2009 Apr 23;113(17):3978-89. doi: 10.1182/blood-2008-10-182709. Epub 2008 Dec 23.